Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raloxifene Hydrochloride

FDA-approved product (tablet, oral), marketed as Evista, Raloxifene Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Raloxifene Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Osteoporosis
  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raloxifene Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raloxifene Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

    NCT07470606 · start 2026-03

    Registered record
    Registry ID
    NCT07470606
    Conditions
    Brain Tumor
    Interventions
    Memantine; Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2031-03
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Tumor
    InterventionMemantine; Raloxifene
    PhasePhase 2
    Registry statusNot yet recruiting

  • Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

    NCT06062810 · start 2025-06-21

    Registered record
    Registry ID
    NCT06062810
    Conditions
    Breast Cancer
    Interventions
    Raloxifene - Usual; Raloxifene - Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Active not recruiting
    Start
    2025-06-21
    Completion
    2026-12-28
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionRaloxifene - Usual; Raloxifene - Study
    PhasePhase 2 / Phase 3
    Registry statusActive not recruiting

  • XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

    NCT06055179 · start 2024-03-08

    Registered record
    Registry ID
    NCT06055179
    Conditions
    Xiao Chai Hu Tang; Irinotecan-induced Diarrhea
    Interventions
    Xiao Chai Hu Tang (XCHT); Placebo; Irinotecan regimen; Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-03-08
    Completion
    2026-12-01
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionXiao Chai Hu Tang; Irinotecan-induced Diarrhea
    InterventionXiao Chai Hu Tang (XCHT); Placebo; Irinotecan regimen; Raloxifene
    PhaseNot applicable
    Registry statusRecruiting

  • Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.

    NCT05172050 · start 2021-01-22

    Registered record
    Registry ID
    NCT05172050
    Conditions
    SARS CoV 2 Infection
    Interventions
    Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2021-01-22
    Completion
    2021-06-12
    Enrolment
    61

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSARS CoV 2 Infection
    InterventionRaloxifene; Placebo
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data

    NCT04736693 · start 2020-09-22

    Registered record
    Registry ID
    NCT04736693
    Conditions
    Osteoporosis
    Interventions
    Raloxifene; Zoledronic Acid
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-09-22
    Completion
    2021-02-18
    Enrolment
    18,028

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionRaloxifene; Zoledronic Acid
    PhaseNot recorded
    Registry statusCompleted

  • Evaluating the Pharmacokinetic Characteristics of AD-101 in Healthy Volunteers

    NCT03764462 · start 2018-12-14

    Registered record
    Registry ID
    NCT03764462
    Conditions
    Osteoporosis
    Interventions
    AD-101 45mg; Raloxifene 60mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-14
    Completion
    2019-02-08
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis
    InterventionAD-101 45mg; Raloxifene 60mg
    PhasePhase 1
    Registry statusCompleted

  • Comparative Antiresorptive Efficacy Discontinuation of Denosumab

    NCT03623633 · start 2018-11-30

    Registered record
    Registry ID
    NCT03623633
    Conditions
    Osteoporosis, Postmenopausal; Osteoporosis
    Interventions
    denosumab; alendronate; raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Active not recruiting
    Start
    2018-11-30
    Completion
    2023-08-01
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal; Osteoporosis
    Interventiondenosumab; alendronate; raloxifene
    PhasePhase 4
    Registry statusActive not recruiting

  • Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women

    NCT03418831 · start 2018-07-17

    Registered record
    Registry ID
    NCT03418831
    Conditions
    Schizophrenia
    Interventions
    Raloxifene Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-07-17
    Completion
    2019-07-30
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionRaloxifene Hydrochloride; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

    NCT03147196 · start 2017-06-27

    Registered record
    Registry ID
    NCT03147196
    Conditions
    Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma
    Interventions
    Bicalutamide; Laboratory Biomarker Analysis; Questionnaire Administration; Raloxifene Hydrochloride
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2017-06-27
    Completion
    2022-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma
    InterventionBicalutamide; Laboratory Biomarker Analysis; Questionnaire Administration; Raloxifene Hydrochloride
    PhasePhase 2
    Registry statusWithdrawn

  • Osteoporosis Treatment in Post-menopausal Women

    NCT03006003 · start 2017-01-01

    Registered record
    Registry ID
    NCT03006003
    Conditions
    Depressive Syndrome
    Interventions
    Raloxifene; Alendronate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2017-01-01
    Completion
    2021-12
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDepressive Syndrome
    InterventionRaloxifene; Alendronate
    PhasePhase 4
    Registry statusUnknown

  • Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder

    NCT03043820 · start 2016-08

    Registered record
    Registry ID
    NCT03043820
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS
    Interventions
    Raloxifene; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08
    Completion
    2021-07-01
    Enrolment
    110

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder; Psychosis NOS
    InterventionRaloxifene; Placebo
    PhasePhase 3
    Registry statusCompleted

  • A Drug-drug Interaction Study of DP-R213

    NCT02654093 · start 2016-01

    Registered record
    Registry ID
    NCT02654093
    Conditions
    Healthy
    Interventions
    Cholecalciferol; Raloxifene; Cholecalciferol and Raloxifene co-administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01
    Completion
    2016-03
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCholecalciferol; Raloxifene; Cholecalciferol and Raloxifene co-administration
    PhasePhase 1
    Registry statusCompleted

  • Efficacy Study of Raloxifene to Induce Ovulation in Polycystic Ovarian Syndrome

    NCT01607320 · start 2012-06

    Registered record
    Registry ID
    NCT01607320
    Conditions
    Polycystic Ovarian Syndrome
    Interventions
    Raloxifene; Clomiphene
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Terminated
    Start
    2012-06
    Completion
    2013-03
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovarian Syndrome
    InterventionRaloxifene; Clomiphene
    PhaseNot applicable
    Registry statusTerminated

  • Selective Estrogen Receptor Modulators (SERMs) - A Potential Treatment for Psychotic Symptoms of Schizophrenia in Men?

    NCT01481883 · start 2012-01

    Registered record
    Registry ID
    NCT01481883
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventions
    Raloxifene Hydrochloride; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2019-02
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    InterventionRaloxifene Hydrochloride; Placebo
    PhasePhase 4
    Registry statusCompleted

  • Bazedoxifene Post Approval Safety Study (PASS) in the European Union (EU)

    NCT01416194 · start 2011-07-25

    Registered record
    Registry ID
    NCT01416194
    Conditions
    Osteoporosis, Postmenopausal
    Interventions
    Bazedoxifene; Bisphosphonate; Raloxifene
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-07-25
    Completion
    2019-04-30
    Enrolment
    10,497

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOsteoporosis, Postmenopausal
    InterventionBazedoxifene; Bisphosphonate; Raloxifene
    PhaseNot recorded
    Registry statusCompleted